Journal of Psychoactive Drugs
August 4, 2025
Meredith C. Meacham, Maha N. Mian, Ralph C. Wang et al.
2 citations
Among U.S. adults who have ever used a hallucinogen, four distinct patterns of lifetime use emerge: a group primarily using psilocybin (16%), a larger group using both LSD and psilocybin (46%), a group mainly using ecstasy (23%), and a group using multiple hallucinogens (15%). Older age is associated with higher odds of being in the LSD/psilocybin class compared with the psilocybin-only class, and non-White participants have higher odds of being in the ecstasy class. These overlapping use patterns suggest that clinical trials and future policies should account for polysubstance hallucinogen experiences.
Journal of Psychoactive Drugs
March 14, 2025
Lukas Bobak, Ian Dorney, Alexsandra Kovacevich et al.
2 citations
In an analysis of 110 Reddit posts from individuals with long COVID who used psilocybin, 78.2% reported any improvement in their symptoms, while 11.8% reported worsening. Among those reporting improvement, 77.9% said the improvement lasted beyond the acute psychedelic experience, and 5.8% reported improvement only during the experience. The most common symptoms were fatigue (47.3%), cognitive impairment (46.4%), and depression (30.0%). The authors suggest that controlled studies comparing social media data for other self-treatments or prospective observational studies of individuals self-treating with psychedelics may be warranted.
Journal of Psychoactive Drugs
August 21, 2023
Caroline Rutherford, Austin Le, Joseph J. Palamar et al.
2 citations
Among nightclub and festival attendees at electronic dance music events in New York City, summer is associated with higher odds of using LSD and psilocybin (shrooms), independent of long-term increases in psilocybin use. Across 15 seasons from summer 2017 through fall 2022, surveys of 3,935 adults found that summer raised the odds of LSD use more than 2.5 times and psilocybin use more than 1.6 times compared to the average across all seasons. Cocaine and ecstasy use decreased over the study period without seasonal variation. The findings suggest summer as a key time for disseminating harm-reduction information for psychedelic users.
Journal of Psychoactive Drugs
May 18, 2026
1 citation
Lifetime use of hallucinogens (LSD, psilocybin, MDMA, ketamine, or PCP) is associated with a modest increase in the odds of valvular heart disease after accounting for sociodemographic factors and other health conditions. In a large US adult sample, 13.2% reported lifetime hallucinogen use. The unadjusted prevalence of VHD was lower among users (3.6%) than non-users (4.7%), but after adjustment the odds rose slightly (adjusted odds ratio 1.08). The authors call for longitudinal studies to confirm this exploratory finding.
Journal of Psychoactive Drugs
May 30, 2025
Brandon Biba, Brian O’shea
1 citation
Analyses of Reddit discussions using Google's cloud-based Natural Language Processing (NLP) show that illicit substances such as heroin and methamphetamine are associated with highly negative general sentiments, whereas psychedelics like Psilocybin, LSD, and Ayahuasca generally evoke neutral to slightly positive sentiments. The findings suggest that online public sentiment toward psychedelics may be growing in acceptance of their therapeutic potential. Limitations include potential selection bias from the Reddit sample and challenges in accurately interpreting nuanced language using NLP.
Journal of Psychoactive Drugs
May 29, 2025
Araam Abboud, Kyle Hua, Hannah Redding et al.
1 citation
A survey of psychiatric patients at a community mental health center found that 62.4% were open to hallucinogenic psilocybin therapy and 60.4% to non-hallucinogenic forms. Patients with major depressive disorder preferred hallucinogenic therapy, while those with borderline personality disorder or post-traumatic stress disorder favored non-hallucinogenic options, possibly due to concerns about the intensity of hallucinogenic experiences. Individuals with substance use disorder showed greater acceptance of both forms than those without. The findings suggest societal stigma is not a major barrier to psilocybin therapy and that non-hallucinogenic forms may offer a more accessible option for some groups.
Journal of Psychoactive Drugs
March 5, 2025
Josephine Yalovitser, Jonah Levine, Cole Zweber et al.
1 citation
A survey of 770 Vermont primary care providers found that two-thirds were familiar with therapeutic use of psychedelics, but fewer than half knew the legal status of LSD, psilocybin, and MDMA. Ninety-six percent were neutral or agreed that psychedelics have high therapeutic potential. The top concerns were effects on youth, risk of psychosis, and traffic safety. Eighty-three percent were not at all or only slightly concerned about inherent dangers. Seventy-seven percent wanted more education. Overall, Vermont PCPs are familiar with psychedelics and cautiously optimistic about their therapeutic role.
Journal of Psychoactive Drugs
March 1, 2025
Alexsandra Kovacevich, Ian Dorney, Lukas Bobak et al.
1 citation
Since the COVID-19 pandemic, smell loss (olfactory dysfunction) has become more common, but effective treatments are scarce. Anecdotal reports suggest that serotonergic psychedelics like LSD and psilocybin might help. Analyzing 125 online posts from people with self-reported smell loss, 108 (86.4%) reported improvements in their sense of smell after using psychedelics. Of those, 55 (50.1%) first noticed improvement during the psychedelic experience, and 42 (38.8%) said the improvement lasted at least one day. No statistical link was found between dose and how long the benefit lasted for either psilocybin or LSD. These findings indicate that further research is needed to explore whether these substances could become a clinical treatment for smell loss.
Journal of Psychoactive Drugs
January 27, 2022
Ciarán Martin Fitzpatrick, B. Anderson, Gabrielle Agin-Liebes et al.
1 citation
A case report described a person with obsessive-compulsive disorder whose symptoms lessened after consuming psilocybin-containing mushrooms. The report prompted a letter arguing that psychedelic research has moved beyond case studies and that journals should prioritize publishing clinical trials over case reports.
Journal of Psychoactive Drugs
November 26, 2020
Heba Diab, Benjamin Malcolm
1 citation
A 39-year-old man with past polysubstance use disorder and depression developed tinnitus after inhaling DMT, though he was also microdosing LSD weekly. The ringing caused distress and anxiety, leading him to seek help from an audiologist, primary care doctor, and psychopharmacologist. Tinnitus lasted several months, but its intensity and his ability to cope improved over time. Taking psilocybin mushrooms worsened the tinnitus on two occasions, after which he stopped using psychedelics. While psychedelics are known to cause acute auditory changes, this is the first probable case linking DMT to persistent tinnitus. The report reviews possible mechanisms connecting psychedelics and tinnitus.
Journal of Psychoactive Drugs
July 3, 2026
Miguel Joaquim Soares Teles Couceiro, Victor José da Conceição Teixeira Amorim Rodrigues, Nuno Manuel Correia Torres
In a patient with generalized anxiety disorder and migraines, mystical-type experiences during ketamine-assisted psychotherapy appeared to contribute to therapeutic improvements. After four intramuscular sessions (0.5-0.9 mg/kg), greater gains followed sessions with higher scores on the Hood Mysticism Scale. The patient attributed progress to the psychological and spiritual impact of the experiences, highlighting the importance of the therapeutic relationship and integration process. This case suggests that subjective mystical experiences may play a meaningful role in therapeutic change during ketamine-assisted psychotherapy.
Journal of Psychoactive Drugs
June 19, 2026
Carla J. Berg, Darcey M. Mccready, Cassidy R. Loparco et al.
Among a sample of young adults with high rates of past-month cannabis use, lifetime and past-year psychedelic use were 27.7% and 11.9%, respectively, with psilocybin/amanita, MDMA, and LSD being most common. Nearly half used psychedelics only for nonmedical purposes. Of those who had ever used, 26.5% had microdosed. Older age, male sex, Black race, metropolitan residence, more depressive symptoms, and more adverse childhood events were linked to lifetime use. Microdosing was associated with not having children, more anxiety, and more adverse childhood events. Mental health symptoms and adverse childhood events were also tied to higher use motives, including expansion, mood enhancement, and symptom management.
Journal of Psychoactive Drugs
June 17, 2026
F. van Dalen, S. C. Tap, S. D. Venema et al.
Mental healthcare professionals generally hold cautiously optimistic views about psychedelic-assisted therapy for substance use disorder, though a minority express hesitancy due to concerns about safety, efficacy, and practical integration challenges. A systematic review of six studies with 966 participants found that greater knowledge and familiarity with psychedelic-assisted therapy predict more positive attitudes. The limited knowledge among professionals highlights a need for targeted education and training to support the responsible integration of this treatment into clinical care.
Journal of Psychoactive Drugs
June 10, 2026
Bruno Pereira Dos Santos, Vítor Camargo Pôrto, Letícia Birk et al.
In Brazil, ecstasy-type drugs are the most commonly seized synthetic drugs, and recent years have seen a shift from MDMA to its analog MDA, possibly due to changes in synthetic routes during the COVID-19 pandemic. Analysis of drug seizures in Rio Grande do Sul found MDA in 31.1% of samples, surpassing MDMA at 25.6%, with MDA detections peaking at 52.6% in 2023. Clinical and forensic cases also showed MDA predominating from 2021 onward. This higher prevalence of MDA indicates a change in ecstasy use patterns, highlighting the need for robust analytical methods and ongoing toxicological monitoring to inform drug surveillance and public health policies.
Journal of Psychoactive Drugs
May 22, 2026
Jamie Walker, Daryle Deering, Bruno Hamish Unger
Ten opioid-dependent people in New Zealand who used ibogaine for detoxification described rapid withdrawal relief, improved mood, reduced anxiety, and periods of sustained abstinence, though some later relapsed. Participants were motivated by desperation to be opioid-free and sought ibogaine because of limited treatment options beyond opioid substitution therapy. They emphasized the importance of safety practices, medical screening, and post-treatment psychosocial support for positive outcomes. The study identified seven themes including motivations, treatment effects on depression and anxiety, and spiritual effects. Ibogaine is legally available by prescription in New Zealand, providing a unique context for understanding user experiences.
Journal of Psychoactive Drugs
March 18, 2026
Jonathan Bendz, Linus Schäfer, David Sjöström et al.
People who are enthusiastic about psychedelics report greater improvements in quality of life from their experiences compared to a general population sample, even after accounting for differences in mindset, setting, motivation, and personality. The study surveyed 1,182 participants (583 enthusiasts and 599 general population) with prior psychedelic use. Enthusiasts scored higher on openness, extraversion, and agreeableness, had more favorable mindsets and settings, and were more motivated by personal growth. Sample membership was the strongest predictor of reported quality-of-life impact, followed by setting, motivation, openness, and mindset. These results clarify how recruiting enthusiasts can inflate reported benefits and highlight the need for representative sampling in psychedelic research.
Journal of Psychoactive Drugs
January 2, 2026
Frederick D. Sancilio, Maghsoud Dariani, Purvi Chavda et al.
A stable salt of psilocin, psilocin mucate (L-130), delivers increased bioavailability and more precise control of therapeutic levels compared to oral psilocybin. In this study, daily dosing of L-130 led to significant reductions in cortisol levels and improved performance on anxiety-related behavioral tasks, including the Elevated Plus Maze, Open Field Test, and Novel Object Recognition Task, while weekly dosing did not generally produce significant results. Clinical assessments and blood analyses suggest L-130 is safe with no toxicological effects. Larger studies are needed to determine optimal doses and dosing schedules.
Journal of Psychoactive Drugs
January 1, 2026
Philip Kamilar-Britt, Alyssa B. Oliva, Mitch Earleywine
Familiarity with treatment options predicts how credible nicotine users find both standard cessation methods and psilocybin-assisted psychotherapy. In a survey of 534 daily nicotine users, those more familiar with a treatment rated it as more credible. Credibility, in turn, predicted interest in trying that treatment. Younger age, lower education, and prior psychedelic use were associated with greater interest in psilocybin-assisted therapy. Tailoring educational materials to increase familiarity may improve treatment engagement and outcomes.
Journal of Psychoactive Drugs
October 10, 2025
Mitch Earleywine, Caitlin Holley, Henry A. Macconnel et al.
Veterans receiving care from the Veterans Affairs system hold a mix of hope, curiosity, and concerns about MDMA-assisted therapy for PTSD. In a story completion task, at least one third of 30 participants mentioned shortcomings of existing treatments, curiosity about the treatment's rationale, hope, and concerns about side effects, subjective effects, and addictive potential. Clear misunderstandings about the molecule, treatment, or its implications appeared in at least 10% of narratives. Allusions to therapist abuse, microdosing, and the role of sitters were rare. These findings can guide development of surveys and psychoeducation materials to address attitudes in larger veteran samples.
Journal of Psychoactive Drugs
January 7, 2025
Fernando Espí Forcén
A patient who used psilocybin without psychedelic-assisted psychotherapy required inpatient psychiatric admission. The case highlights the importance of taking psilocybin in controlled clinical settings. The authors discuss how psychedelic-assisted psychotherapy could have changed the outcome and the role of experiential learning for potential prescribers.